Checkpoint immunotherapy has transformed oncology, yet a substantial fraction of patients fail to respond — and the molecular reasons remain poorly understood. A clearer picture of why certain tumors are intrinsically resistant could reshape how oncologists stratify patients before prescribing anti-PD-1 agents, particularly in colorectal cancer where p53 mutations are nearly universal.
Researchers engineered MC38 colorectal cancer cells harboring two specific Trp53 mutations — G242V and S258I — alongside complete Trp53 deletion, then challenged these lines with anti-PD-1 therapy in vivo. Tumors lacking Trp53 entirely showed dramatically improved immunotherapy responses: CD8+ cytotoxic T cells infiltrated more robustly and underwent clonal expansion, while immunosuppressive regulatory T cells (Tregs) were reduced. The mechanistic explanation centers on mTORC1: wild-type p53 and the tested gain-of-function mutants both upregulate a set of mTORC1 inhibitor genes, keeping mTORC1 activity low and autophagy elevated. When those mutations are present, this suppression is retained. When p53 is absent entirely, mTORC1 signaling surges, autophagy declines, and tumor cells become acutely sensitive to IFN-γ and TNF-α-driven apoptosis — the very cytokines unleashed by activated CD8+ T cells. The team replicated the mTORC1-inhibitor-gene regulation pattern in a human colorectal cancer cell line, strengthening translational relevance.
This finding adds important nuance to a contentious literature: TP53 mutation status alone is an inadequate biomarker for immunotherapy response. What matters is which specific mutation is present and whether it preserves the mTORC1-suppressing transcriptional program. The study is preclinical and primarily cell-line and mouse-model based, so causal conclusions in human tumors remain provisional. Still, the identification of a concrete mechanistic axis — p53 → mTORC1 inhibitor genes → autophagy → sensitivity to immune cytotoxicity — offers a testable framework. If validated in patient cohorts, selective mTORC1 inhibition in p53-mutant tumors resistant to checkpoint blockade could become a rational combination strategy worth clinical exploration.